<DOC>
	<DOCNO>NCT02760797</DOCNO>
	<brief_summary>This open-label , multicenter study design assess safety , pharmacokinetics , pharmacodynamics therapeutic activity emactuzumab RO7009789 administer combination participant advance solid tumor . This study conduct two part : dose escalation stage ( Part 1 ) expansion stage ( Part 2 ) .</brief_summary>
	<brief_title>A Study Emactuzumab RO7009789 Administered Combination Participants With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Eastern Cooperative Oncology Group performance status 0 1 Participants must histologically confirm diagnosis locally advance and/or metastatic triple negative breast cancer , ovarian cancer , gastric cancer , colorectal cancer , pancreatic cancer , melanoma mesothelioma Radiologically measurable clinically evaluable disease per RECIST version 1.1 Life expectancy great equal ( &gt; = ) 16 week Ability comply collection tumor biopsy ; tumor must accessible biopsy Adequate bone marrow , liver , cardiac , renal function Allergy hypersensitivity component either study drug formulation Active untreated central nervous system ( CNS ) metastasis determine compute tomography ( CT ) magnetic resonance image evaluation screen prior radiographic assessment . Participants radiographically stable , asymptomatic previously irradiate lesion eligible provide Participant &gt; = 4 week beyond completion cranial irradiation &gt; /= 3 week corticosteroid therapy Participants leptomeningeal disease , Participants metastases brain stem , midbrain , pons , medulla , within 10 millimeter ( mm ) optic apparatus ( optic nerve chiasm ) exclude History Human Immunodeficiency Virus ( HIV ) Participants active hepatitis B , active hepatitis C , active tuberculosis Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>